Vantage logo

No margin left for error at Acorda

Generic versions of Acorda’s Ampyra are about to flood the market, meaning that the company desperately needs a timely approval in October for its next big hope.

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.